Infection and Drug Resistance (Nov 2024)
Combination Therapy of Trimethoprim-Sulfamethoxazole (TMP-SMZ) and Eravacycline for Treating Elizabethkingia anophelis-Induced Pulmonary Infections: A Case Report
Abstract
Qimei Wei,1,* Wenxia Zuo,2,* Rong Cong,1 Kun Luo,1 Shanshan Dong1 1Department of Clinical Laboratory, Wuhan Asia Heart Hospital, Wuhan, 430022, People’s Republic of China; 2Department of Cardiac Critical Care Medicine, Wuhan Asia Heart Hospital, Wuhan, 430022, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shanshan Dong, Department of Clinical Laboratory, Wuhan Asia Heart Hospital, No. 753 Jinghan Avenue, Jianghan District, Wuhan, 430022, People’s Republic of China, Tel +86 18162516279, Email [email protected]: Elizabethkingia anophelis is an opportunistic pathogen that causes serious life-threatening infections. In this report, we describe a case of pulmonary infection caused by E. anophelis in a young female patient, following cardiac surgery, which was successfully treated with a combination of trimethoprim-sulfamethoxazole (TMP-SMZ) and eravacycline. Additionally, this report provides a summary of high-risk factors for E. anophelis infection, clinical manifestations, and therapeutic options. Given the high degree of antimicrobial drug resistance of the organism and the fact that inappropriate empirical antimicrobial therapy constitutes a risk factor for mortality, our case serves as a valuable reference for similar cases, highlighting potential strategies for effective management.Keywords: Elizabethkingia anophelis, pulmonary infections, trimethoprim-sulfamethoxazole, eravacycline
